NO20070127L - Fremgangsmate for behandling av granuloma annulare eller sarkoid - Google Patents

Fremgangsmate for behandling av granuloma annulare eller sarkoid

Info

Publication number
NO20070127L
NO20070127L NO20070127A NO20070127A NO20070127L NO 20070127 L NO20070127 L NO 20070127L NO 20070127 A NO20070127 A NO 20070127A NO 20070127 A NO20070127 A NO 20070127A NO 20070127 L NO20070127 L NO 20070127L
Authority
NO
Norway
Prior art keywords
sarcoid
procedure
treatment
granuloma
annular
Prior art date
Application number
NO20070127A
Other languages
English (en)
Inventor
Bernard S Goffe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20070127L publication Critical patent/NO20070127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen tilveiebringer en fremgangsmåte for å lindre en granuloma annulare eller en sarkoid sykdom ved å administiere til en pasient som har sykdommen en terapeutisk effektiv mengde av en LFA-1 -antagonist.
NO20070127A 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid NO20070127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57876804P 2004-06-09 2004-06-09
US57909604P 2004-06-10 2004-06-10
PCT/US2005/020342 WO2005123777A2 (en) 2004-06-09 2005-06-08 Method of treating granuloma annulare or sarcoid

Publications (1)

Publication Number Publication Date
NO20070127L true NO20070127L (no) 2007-01-08

Family

ID=35355731

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070127A NO20070127L (no) 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid

Country Status (11)

Country Link
US (1) US7396530B2 (no)
EP (1) EP1756163A2 (no)
JP (1) JP2008507592A (no)
AU (1) AU2005254980A1 (no)
BR (1) BRPI0511305A (no)
CA (1) CA2568570A1 (no)
IL (1) IL179557A0 (no)
MX (1) MXPA06014354A (no)
NO (1) NO20070127L (no)
RU (1) RU2006146939A (no)
WO (1) WO2005123777A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
RU2671516C1 (ru) * 2018-01-10 2018-11-01 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ лечения кольцевидной гранулемы

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
CA2050329A1 (en) 1989-03-09 1990-09-10 Timothy A. Springer Method of treating viral infections using lfa-1
CA2011633C (en) 1989-03-09 2007-05-15 Timothy A. Springer Intercellular adhesion molecule - 2 and its binding ligands
WO1990013281A2 (en) 1989-04-28 1990-11-15 Baylor College Of Medicine Method of suppressing hiv infection
AU645016B2 (en) 1989-06-02 1994-01-06 Johns Hopkins University School Of Medicine, The Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
WO1991018011A1 (en) 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
HUT69725A (en) 1991-10-01 1995-09-28 Gen Hospital Corp Process for producing compositions for preventing allograft rejection
AU2777092A (en) 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB2266664A (en) 1992-04-28 1993-11-10 Pierre Francois Piguet Monoclonal antibodies for prophylaxis and treatment of pulmonary fibrosis
JPH08500826A (ja) 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
EP1516629B1 (en) * 1996-11-27 2013-04-03 Genentech, Inc. Humanized anti CD-11a antibodies
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
FR2763072B1 (fr) 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
AR030817A1 (es) * 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona

Also Published As

Publication number Publication date
IL179557A0 (en) 2007-05-15
CA2568570A1 (en) 2005-12-29
RU2006146939A (ru) 2008-07-20
AU2005254980A1 (en) 2005-12-29
JP2008507592A (ja) 2008-03-13
WO2005123777A2 (en) 2005-12-29
WO2005123777A3 (en) 2006-03-02
MXPA06014354A (es) 2007-02-19
EP1756163A2 (en) 2007-02-28
US20060013818A1 (en) 2006-01-19
BRPI0511305A (pt) 2007-12-04
US7396530B2 (en) 2008-07-08

Similar Documents

Publication Publication Date Title
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
BR0314760A (pt) Compostos orgânicos
BRPI0510274A (pt) epìtopos relacionados à doença celìaca
NO20074509L (no) Kombinasjon av organiske forbindelser
NO20070906L (no) Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat
BRPI0416628A (pt) uso de compostos orgánicos
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2008050329A3 (en) Novel sirnas and methods of use thereof
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20083836L (no) N-hydroksyakrylamidforbindelser
MX2008013827A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
WO2007019153A3 (en) Methods for treating hypertension
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
MA56187B1 (fr) Traitements de l'angio-oedème héréditaire
BRPI0518690A2 (pt) tratamento de doenÇa inflamatària do intestino
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
NO20074252L (no) Forbindelser og anvendelser derav
EA200970436A1 (ru) Соединения карбамата для лечения депрессии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application